The JAK/STAT conundrum with mutational heterogeneity, immune defects, and the emergence of targeted therapies
- 3 August 2025
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 21 (8) , 1083-1100
Abstract
The Janus kinase/signal transducer and activator of transcription signaling pathway orchestrates crucial aspects of immune regulation, including cytokine signaling, cellular proliferation, differentiation, and apoptosis. Dysregulation of this pathway due to gain- or loss-of-function mutations significantly contributes to the development of inborn errors of immunity and various immune-mediated disorders. Understanding the molecular basis of these abnormalities is fundamental for enhancing diagnostic precision and developing targeted therapies. A bibliographic search was conducted in PubMed and MEDLINE for articles published up to June 2025. The review offers a comprehensive overview of the structural and functional features of JAK/STAT family proteins, the intrinsic regulatory mechanisms, and the immunopathological consequences of STAT1, STAT3, and STAT6 GOF mutations. Recent clinical advances, particularly the therapeutic impact of JAK inhibitors and emerging novel molecules, are critically discussed, emphasizing the integration of molecular insights into clinical practice. Advances in the molecular characterization of JAK/STAT pathway dysregulation have opened new avenues for precision medicine approaches. While JAKinibs have shown promising outcomes, further research is needed to optimize therapeutic strategies, identify predictive biomarkers, and refine patient selection to maximize clinical benefits. Novel targeted therapies can reshape the management of JAK/STAT-related diseases in the coming years.Keywords
Funding Information
- Marmara University (ADT-2022-10661)
This publication has 122 references indexed in Scilit:
- Hematopoietic Stem Cell Transplantation in Patients with Heterozygous STAT1 Gain-of-Function MutationJournal of Clinical Immunology, 2018
- The molecular details of cytokine signaling via the JAK/STAT pathwayProtein Science, 2018
- Severe Early-Onset Combined Immunodeficiency due to Heterozygous Gain-of-Function Mutations in STAT1Journal of Clinical Immunology, 2016
- Gain‐of‐function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC)European Journal of Immunology, 2015
- PIAS/SUMO: new partners in transcriptional regulationCellular and Molecular Life Sciences, 2003
- The STAT Protein Family2003
- SO MANY LIGANDS, SO FEW TRANSCRIPTION FACTORS: A NEW PARADIGM FOR SIGNALING THROUGH THE STAT TRANSCRIPTION FACTORSCytokine, 2001
- Nuclear targeting signal recognition: a key control point in nuclear transport?BioEssays, 2000
- A novel cytokine‐inducible gene CIS encodes an SH2‐containing protein that binds to tyrosine‐phosphorylated interleukin 3 and erythropoietin receptors.The EMBO Journal, 1995
- A direct signaling pathway through tyrosine kinase activation of SH2 domain-containing transcription factorsJournal of Leukocyte Biology, 1995